Statement of Beneficial Ownership (sc 13d)
January 22 2019 - 10:06AM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C.20549
SCHEDULE
13D
Under the Securities Exchange Act of 1934
(Amendment No. __)
GENE
BIOTHERAPEUTICS INC.
(FORMERLY
TAXUS CARDIUM PHARMACEUTICALS GROUP INC.)
(Name
of Issuer)
Common
Stock, par value $0.001 per share
(Title
of Class of Securities)
86767104
1
(CUSIP
Number)
Barry
Rothenburg
71-32
Austin Street, Second Floor
Forest
Hills, NY 11375
Phone:
(718) 544-2900
(Name,
Address and Telephone Number of Person Authorized to Receive Notices and Communications)
January
15, 2019
(Date
of Event which Requires Filing of this Statement)
If
the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule
13D, and is filing this schedule because of 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box [ ].
Note:
Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See 240.13d-7(b)
for other parties to whom copies are to be sent.
*The
remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the
subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in
a prior cover page.
The
information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section
18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act
but shall be subject to all other provisions of the Act (however, see the Notes).
SCHEDULE
13D
1
|
NAMES OF REPORTING PERSONS
I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)
|
|
|
|
Barry
Rothenburg
|
2
|
CHECK
THE APPROPRIATE BOX IF A MEMBER OF A GROUP*
|
|
|
|
(a)
[ ]
(b)
[X]
|
3
|
SEC
USE ONLY
|
|
|
4
|
SOURCE
OF FUNDS (See Instructions)
|
|
|
|
Personal
Funds of Reporting Person
|
5
|
CHECK
IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(D) OR 2(E)
|
|
|
|
[ ]
|
6
|
CITIZENSHIP
OR PLACE OF ORGANIZATION
|
|
|
|
Forest
Hills, NY 11375 USA
|
|
7
|
SOLE VOTING POWER
|
|
|
|
|
|
1,603,856
|
NUMBER OF
|
8
|
SHARED VOTING POWER
|
SHARES
|
|
|
BENEFICIALLY
|
|
0
|
OWNED BY
|
9
|
SOLE DISPOSITIVE POWER
|
EACH
|
|
|
REPORTING
|
|
1,603,856
|
PERSON
|
10
|
SHARED DISPOSITIVE POWER
|
WITH
|
|
|
|
|
0
|
11
|
AGGREGATE
AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
|
|
|
|
1,603,856
|
12
|
CHECK
BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (See Instructions)
|
|
|
|
[ ]
|
13
|
PERCENT
OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
|
|
|
|
11.2%
|
14
|
TYPE
OF REPORTING PERSON (See Instructions)
|
|
|
|
Individual
(IN)
|
Item
1. Security and Issuer
This
Schedule 13D relates to an aggregate of 1,603,856 shares of common stock, par value $0.001 per share (the “Common Stock”)
of Gene Biotherapeutics Inc., formerly named Taxus Cardium Pharmaceuticals Group Inc. (the “Company”), a Delaware
corporation. The Company’s principal executive offices are located at 11658 Sorrento Valley Road, Suite #14, San Diego,
CA 92121.
Item
2. Identity and Background
|
(a)
|
Reporting
Person: Barry Rothenburg as an individual investor
|
|
|
|
|
(b)
|
Principal
business address: 71-32 Austin Street, 2
nd
Floor, Forest Hills, NY USA
|
|
|
|
|
(c)
|
Principal
occupation: real estate investment and property management
|
|
|
|
|
(d)
|
During
the past five years, the Reporting Person was not the party to and the conviction any criminal Proceedings
|
|
|
|
|
(e)
|
During
the past five years, the Reporting Person was not a party to a civil proceeding or administrative body of competent jurisdiction
and as a result of such proceeding was or is subject to judgement, decree or final order enjoining future violations of, or
prohibiting of mandating activities subject to federal or state securities laws or finding any violation with respect to such
laws.
|
|
|
|
|
(f)
|
The
Reporting Person is a citizen of the United States of America
|
Item
3. Source and Amount of Funds or Other Considerations
The
Reporting Person has been a long-term investor in the Company and acquired 1,603,856 shares of Common Stock at a total
purchase price of $750,575 at an average purchase price of $0.47 per share, which represents 11.2% of the outstanding Common
Stock of the Company, through open market purchases.
Item
4. Purpose of Transaction
Long-term
investment.
Item
5. Interest in Securities of the Issuer
(a)
|
The
Reporting Person beneficially owns 1,603,856 shares of Common Stock of the issuer, representing 11.2% of the
Issuer’s outstanding Common Stock as of December 31, 2018
|
|
|
(b)
|
The
Reporting Person has sole voting and dispositive power over any of the shares reported herein.
|
|
|
(c)
|
Not
applicable.
|
|
|
(d)
|
Not
applicable.
|
|
|
(e)
|
Not
applicable.
|
Item
6. Contracts, Arrangements, Understandings or Relationships with Respect to Securities
of the Issuer
None.
Item
7. Material to Be Filed as Exhibits
None.
Signature
After
reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true,
complete and correct.
1.22.19
|
|
Dated
|
|
|
|
/s/
Barry Rothenburg
|
|
Signature
|
|
|
|
Barry
Rothenburg / Individual
|
|
Name/Title
|
|
The
original statement shall be signed by each person on whose behalf the statement is filed or his authorized representative. If
the statement is signed on behalf of a person by his authorized representative (other than an executive officer or general partner
of this filing person), evidence of the representative’s authority to sign on behalf of such person shall be filed with
the statement, provided, however, that a power of attorney for this purpose which is already on file with the Commission may be
incorporated by reference. The name and any title of each person who signs the statement shall be typed or printed beneath his
signature.
Attention:
Intentional misstatements or omissions of fact constitute Federal criminal violations (See 18 U.S.C. 1001).
Taxus Cardium Pharmaceut... (CE) (USOTC:CRXM)
Historical Stock Chart
From Apr 2024 to May 2024
Taxus Cardium Pharmaceut... (CE) (USOTC:CRXM)
Historical Stock Chart
From May 2023 to May 2024